| Literature DB >> 30402044 |
Andrzej P Herman1, Dorota Tomaszewska-Zaremba1, Marta Kowalewska2, Aleksandra Szczepkowska2, Małgorzata Oleszkiewicz2, Agata Krawczyńska1, Maciej Wójcik1, Hanna Antushevich1, Janina Skipor2.
Abstract
The study was designed to examine whether the administration of neostigmine (0.5 mg/animal), a peripheral inhibitor of acetylcholinesterase (AChE), during an immune/inflammatory challenge provoked by intravenous injection of bacterial endotoxin-lipopolysaccharide (LPS; 400 ng/kg)-attenuates the synthesis of proinflammatory cytokines in the ovine preoptic area (POA), the hypothalamic structure playing an essential role in the control of the reproduction process, and in the choroid plexus (CP), a multifunctional organ sited at the interface between the blood and cerebrospinal fluid in the ewe. Neostigmine suppressed (p < 0.05) LPS-stimulated synthesis of cytokines such as interleukin- (IL-) 1β, IL-6, and tumor necrosis factor (TNF) α in the POA, and this effect was similar to that induced by the treatment with systemic AChE inhibitor-donepezil (2.5 mg/animal). On the other hand, both AChE inhibitors did not influence the gene expression of these cytokines and their corresponding receptors in the CP. It was found that this structure seems to not express the neuronal acetylcholine (ACh) receptor subunit alpha-7, required for anti-inflammatory action of ACh. The mechanism of action involves inhibition of the proinflammatory cytokine synthesis on the periphery as well as inhibition of their de novo synthesis rather in brain microvessels and not in the CP. In conclusion, it is suggested that the AChE inhibitors incapable of reaching brain parenchyma might be used in the treatment of neuroinflammatory processes induced by peripheral inflammation.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30402044 PMCID: PMC6198615 DOI: 10.1155/2018/9150207
Source DB: PubMed Journal: Mediators Inflamm ISSN: 0962-9351 Impact factor: 4.711
The scheme of the experiment.
| Group | No. of animals | Experimental treatment I | Dose | Experimental treatment II | Dose | |
|---|---|---|---|---|---|---|
| 1 | Control | 6 | NaCl | 0 | NaCl | 0 |
| 2 | LPS treated | 6 | NaCl | 0 | LPS | 400 |
| 3 | Donepezil treated | 6 | Donepezil | 2.5 | NaCl | 0 |
| 4 | Neostigmine treated | 6 | Neostigmine | 0.5 | NaCl | 0 |
| 5 | Donepezil + LPS treated | 6 | Donepezil | 2.5 | LPS | 400 |
| 6 | Neostigmine + LPS treated | 6 | Neostigmine | 0.5 | LPS | 400 |
| Total number of animals | 36 | |||||
Full names and abbreviations of all genes analysed by Real-Time PCR.
| GenBank acc. no. | Gene | Amplicon size | Forward/reverse | Sequence | Reference |
|---|---|---|---|---|---|
| NM_001034034 |
| 134 | Forward | AGAAGGCTGGGGCTCACT | [ |
| Reverse | GGCATTGCTGACAATCTTGA | ||||
| U39357 |
| 168 | Forward | CTTCCTTCCTGGGCATGG | [ |
| Reverse | GGGCAGTGATCTCTTTCTGC | ||||
| BC108088.1 |
| 115 | Forward | CTGGGGACCTACGGGATATT | [ |
| Reverse | GACATGACCGGCTTGAAAAT | ||||
| X54796.1 |
| 137 | Forward | CAGCCGTGCAGTCAGTAAAA | [ |
| Reverse | GAAGCTCATGCAGAACACCA | ||||
| NM_001206735.1 |
| 124 | Forward | GGGAAGGGTCCACCTGTAAC | [ |
| Reverse | ACAATGCTTTCCCCAACGTA | ||||
| NM_001046210.1 |
| 161 | Forward | CGCCAGGCATACTCAGAAA | [ |
| Reverse | GAGAACGTGGCAGCTTCTTT | ||||
| NM_001308595.1 |
| 145 | Forward | AGGATCTGGGATGTCAACCA | [ |
| Reverse | CATGGATCCCCAGGAACATA | ||||
| NM_001009392.1 |
| 165 | Forward | GTTCAATCAGGCGATTTGCT | [ |
| Reverse | CCTGCGATCTTTTCCTTCAG | ||||
| NM_001110785 |
| 149 | Forward | TCAGCGACTCCGGAAACTAT | [ |
| Reverse | CCGAGGACTCCACTCACAAT | ||||
| XM_004016974 |
| 139 | Forward | GGCTTGCCTCCTGAAAAACC | [ |
| Reverse | ACTTCTCTGTTGCCCACTCAG | ||||
| NM_001024860 |
| 153 | Forward | CAAATAACAAGCCGGTAGCC | [ |
| Reverse | AGATGAGGTAAAGCCCGTCA | ||||
| NM_174674 |
| 137 | Forward | AGGTGCCGGGATGAAATGTT | [ |
| Reverse | CAGAGGCTGCAGTTCAGACA | ||||
| NM_001040490 |
| 122 | Forward | ACCTTCTTCCTCCTCCCAAA | [ |
| Reverse | AGAAGCAGACCCAATGCTGT | ||||
| BC_149340 |
| 114 | Forward | TGGAAGCCAGACATTCTCCT | [ |
| Reverse | GATGCCTGGAGGGAGGTACT |
Figure 1Effect of lipopolysaccharide (LPS; 400 ng/kg; iv.) and acetylcholinesterase inhibitors: donepezil (2.5 mg/animal; iv.) and neostigmine (0.5 mg/animal; iv.) injections on the serum concentration of IL-1β in the samples collected three hours after the LPS treatment. The data are presented as the mean value ± SEM. Different capital letters indicate significant differences according to a two-way ANOVA followed by Fisher's post hoc test. Statistical significance was defined at p < 0.05.
Figure 2Effect of lipopolysaccharide (LPS; 400 ng/kg; iv.) and acetylcholinesterase inhibitors: donepezil (2.5 mg/animal; iv.) and neostigmine (0.5 mg/animal; iv.) injections on the level of proinflammatory cytokines—interleukin- (IL-) 1β (a), IL-6 (b), and tumor necrosis factor (TNF) α (c) in the preoptic area of the hypothalamus. The data are presented as the mean value ± SEM. Different capital letters indicate significant differences according to a two-way ANOVA followed by Fisher's post hoc test. Statistical significance was defined at p < 0.05.
Effect of lipopolysaccharide (LPS; 400 ng/kg; iv.) and acetylcholinesterase inhibitors: donepezil (2.5 mg/animal; iv.) and neostigmine (0.5 mg/animal; iv.) injections on the relative gene expression (mean ± SEM; n = 6 animals per group) of proinflammatory cytokines, their corresponding receptors, and neuronal acetylcholine receptor in the preoptic area of the ovine hypothalamus.
| Gene | Preoptic area of the hypothalamus | |||||
|---|---|---|---|---|---|---|
| Control | Don. | Neo. | LPS | Don. + LPS | Neo. + LPS | |
|
| 1 ± 0.1A | 1.2 ± 0.1A | 0.9 ± 0.1A | 4.4 ± 0.4C | 3.2 ± 0.3B | 3.1 ± 0.2B |
|
| 1 ± 0.2A | 1 ± 0.2A | 1.1 ± 0.2A | 1.7 ± 0.2B | 1.4 ± 0.2AB | 1.4 ± 0.1AB |
|
| 1 ± 0.1A | 0.8 ± 0.1A | 1.1 ± 0.1A | 1.6 ± 0.2B | 1.8 ± 0.2B | 1.5 ± 0.1B |
|
| 1 ± 0.1A | 0.9 ± 0.1A | 0.9 ± 0.1A | 2.7 ± 0.5B | 2.1 ± 0.2B | 2.3 ± 0.2B |
|
| 1 ± 0.1A | 0.9 ± 0.1A | 1.1 ± 0.2A | 13.1 ± 0.1C | 4.7 ± 0.6B | 5.3 ± 0.3B |
|
| 1 ± 0.1A | 0.8 ± 0.1A | 0.9 ± 0.1A | 1 ± 0.1A | 1 ± 0.1A | 0.9 ± 0.1A |
|
| 1 ± 0.1A | 0.9 ± 0.1A | 1 ± 0.1A | 1.3 ± 0.1B | 1.3 ± 0.1B | 1.1 ± 0.1A |
|
| 1 ± 0.1A | 1 ± 0.1A | 1 ± 0.1A | 1.4 ± 0.1B | 1 ± 0.1A | 1.1 ± 0.1A |
|
| 1 ± 0.1A | 1 ± 0.2A | 1 ± 0.2A | 1.2 ± 0.1A | 1.2 ± 0.1A | 1.1 ± 0.1A |
|
| 1 ± 0.1A | 1 ± 0.1A | 1 ± 0.1A | 1.4 ± 0.1B | 1.2 ± 0.1AB | 1.2 ± 0.1AB |
|
| 1 ± 0.1A | 1 ± 0.1A | 1 ± 0.1A | 1.3 ± 0.1B | 1.2 ± 0.1AB | 1.2 ± 0.1AB |
IL-1β: interleukin-1β; IL1R1 and IL1R2: interleukin receptor types 1 and 2; IL1RN: interleukin-1 receptor antagonist; IL-6: interleukin-6; IL6R: glycoprotein 130; TNF: tumor necrosis factor; TNFRSF1A and B: tumor necrosis factor receptor types 1 and 2; CHRNA7: neuronal acetylcholine receptor subunit alpha-7. The gene expression data were normalised to the average relative level of gene expression in the control group of ewes, which was set to 1.0. Different capital letters indicate significant (p < 0.05) differences according to a two-way ANOVA followed by Fisher's post hoc test.
Effect of lipopolysaccharide (LPS; 400 ng/kg; iv.) and acetylcholinesterase inhibitors: donepezil (2.5 mg/animal; iv.) and neostigmine (0.5 mg/animal; iv.) injections on the relative gene expression (mean ± SEM; n = 6 animals per group) of proinflammatory cytokines and their corresponding receptors in the ovine choroid plexus.
| Gene | Choroid plexus | |||||
|---|---|---|---|---|---|---|
| Control | Don. | Neo. | LPS | Don. + LPS | Neo. + LPS | |
|
| 1 ± 0.2A | 0.6 ± 0.1A | 0.5 ± 0.1A | 4.3 ± 1.5B | 4 ± 0.7B | 5.7 ± 1.4B |
|
| 1 ± 0.2A | 0.8 ± 0.1A | 0.9 ± 0.1A | 2.1 ± 0.5B | 2.2 ± 0.3B | 2.1 ± 0.2B |
|
| 1 ± 0.2A | 0.6 ± 0.1A | 1.1 ± 0.3A | 2.9 ± 0.7B | 3.7 ± 0.7B | 4.4 ± 0.9B |
|
| 1 ± 0.1A | 1 ± 0.1A | 1.3 ± 0.1A | 9.4 ± 0.6B | 12.4 ± 1.3B | 12.7 ± 2.5B |
|
| 1 ± 0.4A | 0.9 ± 0.1A | 1.2 ± 0.3A | 84 ± 27B | 84 ± 9B | 123 ± 40B |
|
| 1 ± 0.1AC | 1 ± 0.1A | 1.1 ± 0.0A | 0.8 ± 0.1BC | 0.9 ± 0.1ABC | 0.7 ± 0.1B |
|
| 1 ± 0.2A | 0.7 ± 0.1A | 0.9 ± 0.1A | 1.7 ± 0.2B | 2 ± 0.2B | 1.8 ± 0.4B |
|
| 1 ± 0.1A | 0.7 ± 0.1A | 1 ± 0.1A | 1.9 ± 0.6B | 1.6 ± 0.2B | 1.9 ± 06B |
|
| 1 ± 0.1A | 0.8 ± 0.1A | 1 ± 0.1A | 1.3 ± 0.1B | 1.4 ± 0.1B | 1.4 ± 0.1B |
|
| 1 ± 0.1AB | 0.8 ± 0.1A | 0.8 ± 0.1A | 1.6 ± 0.3C | 1.7 ± 0.3C | 1.4 ± 0.2BC |
IL-1β: interleukin-1β; IL1R1 and IL1R2: interleukin receptor types 1 and 2; IL1RN: interleukin-1 receptor antagonist; IL-6: interleukin-6; IL6R: glycoprotein 130; TNF: tumor necrosis factor; TNFRSF1A and B: tumor necrosis factor receptor types 1 and 2; TLR4: toll-like receptor 4. The gene expression data were normalised to the average relative level of gene expression in the control group of ewes, which was set to 1.0. Different capital letters indicate significant (p < 0.05) differences according to a two-way ANOVA followed by Fisher's post hoc test.